Human xenobiotic metabolizing esterases in liver and blood.
Esterases in human liver microsomes hydrolysed fluazifop-butyl (Vmax 9.8 +/- 1.6 mumol/min/g tissue), paraoxon (Vmax 47.4 +/- 7.5 nmol/min/g tissue) and phenylacetate (Vmax 57 +/- 8 mumol/min/g tissue), whereas esterases found in the human liver cytosol hydrolysed fluazifop-butyl (Vmax 10.0 +/- 0.5 mumol/min/g tissue) and phenylacetate (Vmax 37 +/- 2.9 mumol/min/g tissue) but not paraoxon. Human plasma esterase hydrolysed fluazifop-butyl (Vmax 0.09 +/- 0.006 mumol/min/mL), paraoxon (Vmax 210 +/- 14 nmol/min/mL) and phenylacetate (Vmax 250 +/- 17 mumol/min/mL). Inhibitory studies using paraoxon, bis-nitrophenol phosphate and mercuric chloride indicated fluazifop-butyl hydrolysis involved carboxylesterase in liver microsomes and cytosol, and cholinesterase and carboxylesterase in plasma. Phenylacetate hydrolysis involved arylesterase in plasma, both arylesterase and carboxylesterase in liver microsomes and carboxylesterase in liver cytosol. Plasma hydrolysis is less important and overall esterase activity is lower in humans than in the rat which is therefore a poor model.
McCracken
N W
NW
Toxicology Unit, Medical School, University of Newcastle upon Tyne NE2 4HH, U.K.
Blain
P G
PG
Williams
F M
FM
D000328:Adult; D043303:Aryldialkylphosphatase; D004095:Dihydropyridines / Q000652:urine; D004912:Erythrocytes / Q000201:enzymology*; D004950:Esterases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000201:enzymology*; D008297:Male; D010648:Phenylacetates / Q000378:metabolism; D011725:Pyridines / Q000378:metabolism; D013347:Subcellular Fractions / Q000378:metabolism; D015262:Xenobiotics / Q000378:metabolism*
D004095:Dihydropyridines; D010648:Phenylacetates; D011725:Pyridines; D015262:Xenobiotics; C050585:fluazifop-butyl; C050582:fluazifop; D004950:Esterases; D043303:Aryldialkylphosphatase; C025136:phenylacetic acid